Mammalian Nod2 is an intracellular protein that is implicated in the innate immune response to the bacterial cell wall and is associated with the development of Crohn's disease, Blau syndrome, and gastrointestinal cancers. Nod2 is required for an immune response to muramyl dipeptide (MDP), an immunostimulatory fragment of bacterial cell wall, but it is not known whether MDP binds directly to Nod2. We report the expression and purification of human Nod2 from insect cells. Using novel MDP self-assembled monolayers (SAMs), we provide the first biochemical evidence for a direct, high-affinity interaction between Nod2 and MDP.
MammalianNod2 is an intracellular protein that is implicated in the innate immune response to the bacterial cell wall and is associated with the development of Crohn's disease, Blau syndrome, and gastrointestinal cancers. Nod2 is required for an immune response to muramyl dipeptide (MDP), an immunostimulatory fragment of bacterial cell wall, but it is not known whether MDP binds directly to Nod2. We report the expression and purification of humanNod2 from insect cells. Using novel MDP self-assembled monolayers (SAMs), we provide the first biochemical evidence for a direct, high-affinity interaction between Nod2 and MDP.
The innate immune system is
the body’s first line of defense against invading pathogens.[1,2] This ancient system has evolved to exist in a symbiotic relationship
with commensal bacteria and at the same time to recognize and destroy
virulent bacteria.[1−3] Chronic inflammatory diseases such as asthma, rheumatoid
arthritis, and Crohn’s disease are thought to arise from an
inappropriate innate immune response to bacteria.[4−9] Chronic inflammation has also been shown to lead to a variety of
types of cancers, including gastric, colon, and lung cancer.[10]MammalianNod2 is an intracellular protein
that is involved in
the signaling response to bacterial cell wall fragments.[11,12] Mutations in Nod2 correlate with the development of Crohn’s
disease, a chronic inflammatory disease of the gastrointestinal tract.[13−15] To generate the proper immunological response, the Nod2 signaling
pathway must recognize bacteria. The biochemical mechanism by which
Nod2 detects bacteria is not known, but it has been proposed that
Nod2 senses bacterial cell wall fragments directly. Nod2 could sense
bacterial cell wall fragments through at least three mechanisms: (1)
a direct interaction, (2) a mediated interaction, or (3) a signaling
relay. The mechanism of activation remains unresolved because until
now the proper tools to probe the mechanism have been unavailable.Nod2 is essential for the cellular response to a small fragment
of bacterial cell wall, muramyl dipeptide (MDP), consisting of one
carbohydrate and two amino acids. The biologically relevant isomer
is MDP-(d) (1) (Figure 1).[12,16] MDP is found in both Gram-negative and Gram-positive
bacteria. Cellular and in vivo assays have shown that when mammalian
cells expressing Nod2 are treated with MDP, an inflammatory response
is activated via the NF-κB and MAP kinase pathways.[17−20] Moreover, the response is not observed if MDP-(l) (2), a diastereomer of 1 (Figure 1), is used in the cellular assays. For this reason, in the
literature MDP is often called the “ligand” for Nod2
signaling.[21] However, there are no biochemical
or biophysical data that demonstrate an interaction between the two
molecules.[22] The purpose of our investigation
was to determine whether Nod2 and MDP interact in vitro. We developed
an expression system and a biochemical assay using synthetic probes
to investigate this question.
Figure 1
Muramyl dipeptides. MDP-(d) is the
biologically relevant
isomer; MDP-(l) is a synthetic diastereomer of the compound
found in nature.
Muramyl dipeptides. MDP-(d) is the
biologically relevant
isomer; MDP-(l) is a synthetic diastereomer of the compound
found in nature.HumanNod2 is a large protein (1040 residues, 110
kD) with multiple
domains: two N-terminal caspase recruitment domains (CARDs), a central
nucleotide oligomerization domain (NOD), and a C-terminal leucine-rich
repeat (LRR) domain.[16] To determine whether
Nod2 interacts directly with MDP, we first expressed a Flag-tagged
version of Nod2 using baculovirus-infected Sf21 cells [Supporting Information (SI) Figure 1a] with a
yield of 1 mg/L. Circular dichroism spectroscopy and limited proteolysis
experiments were consistent with Nod2 being a folded protein (SI Figure 1b,c).With purified Nod2 in
hand,
we developed a surface plasmon resonance
(SPR) assay to assess binding to MDP. Initial attempts to develop
an SPR assay with biotinylated MDP[23] failed,
as we observed significant nonspecific binding of Nod2 to the streptavidin/biotin
chip lacking MDP (SI Figure 2). To develop
the SPR assay, we coupled 6-amino-MDP (3 and 4; Figure 1) directly to the chip without the
use of biotin. 3 and 4 are synthetic intermediates
of the biotinylated MDPs that have been shown to activate Nod2 in
the appropriate manner.[23] Using methodology
developed by Whitesides and co-workers, we prepared carboxy-terminated
alkanethiol self-assembled monolayers (SAMs) and then used on-chip N-hydroxysuccinimide (NHS)/1-ethyl-3-(3-dimethylaminopropyl)carbodiimide
(EDC) activation of the carboxylic acid (Figure 2)[24] to couple the 6-amino-MDPs to the
chip surface.
Figure 2
Synthesis
of the MDP chip. A mixed SAM consisting of 1 mol % hexa(ethylene
glycol)carboxylic acid [(EG)6CO2H]-terminated
thiol in tri(ethylene glycol) [(EG)3OH])-terminated thiol
was prepared. The carboxylic acid groups were then activated with
NHS and EDC to form NHS esters. Displacement of NHS esters with the
amino groups of MDPs formed amide bonds. Excess NHS esters were deactivated
with ethanolamine.
A typical SPR assay uses four sensor lanes on
a single chip.[25] In the assay, we included
two controls: (1)
the isoglutamine diastereomer of MDP (4; Figure 1), which does not activate the Nod2 pathway, and
(2) an ethanolamine-capped monolayer (Figure 2). A typical assay setup involved flowing Nod2 over each lane of
the sensor chip and observing changes in resonance units (RU). The
assay was robust and allowed the screening of a wide variety of conditions.
There was lower background binding of Nod2 to the synthetic chip relative
to the biotin chip (SI Figures 2 and 3).Synthesis
of the MDP chip. A mixed SAM consisting of 1 mol % hexa(ethylene
glycol)carboxylic acid [(EG)6CO2H]-terminated
thiol in tri(ethylene glycol) [(EG)3OH])-terminated thiol
was prepared. The carboxylic acid groups were then activated with
NHS and EDC to form NHS esters. Displacement of NHS esters with the
amino groups of MDPs formed amide bonds. Excess NHS esters were deactivated
with ethanolamine.Nod2 bound to MDP with high affinity (Figure 3). The biologically active MDP, 3-Lane, bound to Nod2
with KD = 51 ± 18 nM. Surprisingly,
we found that Nod2 was able to bind to both isomers of MDP (Figure 3), as Nod2 bound to 4-Lane with KD = 150 ± 24 nM, which is only slightly
higher than the KD observed for 3-Lane. Thus, the isoglutamine stereochemistry is not a key
recognition determinant. To demonstrate that binding of Nod2 to the
MDP chip was indeed specific, a competition study was performed. When
Nod2 was pretreated with either 3 or 4,
diminished binding to the chip was observed (Figure 4). Encouragingly, the competition data showed the same trend
as the on-chip data, namely, that the free d isomer of MDP
is a better competitor than the free l isomer. These data
suggest that Nod2 senses bacterial cell wall fragments by binding
directly to them.
Figure 3
Nod2 binds to MDPs 3 and 4 with
high
affinities. Nod2 (pH 6.0) was applied to the MDP chip at varying concentrations
at a rate of 3 mL min–1. After 10 min, the resonance
signal was recorded and then plotted after subtraction of the ethanolamine
background. The data were fitted to a standard one-site binding model
by nonlinear regression analysis using Prism 4 (GraphPad).
Figure 4
Binding of Nod2 to the MDP chip is specific. Nod2 [pH
5.5, 0.5
μM, in either the presence or the absence of free MDP (1 μM)]
was applied to the MDP chip. The relative resonance signal was recorded
after 10 min.
Nod2 binds to MDPs 3 and 4 with
high
affinities. Nod2 (pH 6.0) was applied to the MDP chip at varying concentrations
at a rate of 3 mL min–1. After 10 min, the resonance
signal was recorded and then plotted after subtraction of the ethanolamine
background. The data were fitted to a standard one-site binding model
by nonlinear regression analysis using Prism 4 (GraphPad).Binding of Nod2 to the MDP chip is specific. Nod2 [pH
5.5, 0.5
μM, in either the presence or the absence of free MDP (1 μM)]
was applied to the MDP chip. The relative resonance signal was recorded
after 10 min.At low concentrations, the MDP isomers 2 and 4 do not activate the NF-κB response via
Nod2 in cellular
assays.[18,23] However, using the established cellular
NF-κB luciferase reporter assay and transfected Nod2, we showed
that MDP-(l) is able to activate the pathway at higher concentrations
(Figure 5). The NF-κB activation observed
in the absence of transfected Nod2 DNA is the result of low levels
of endogenous Nod2 in Hek293T cells.[26] The
cellular assay results demonstrate that both isomers of MDP are able
to activate the Nod2/NF-κB pathway, which is consistent with
the binding data showing that Nod2 can bind one isomer better than
the other. Cellular potencies often do not exactly match their in
vitro KD values.[27,28] We found that the cellular activation parallels the in vitro binding
but at slightly lower potency.
Figure 5
MDP-(l) (2) activates
the Nod2/NF-κB
pathway at higher concentrations. Hek293T cells were transfected with
(±)-Nod DNA (0.1 ng), NF-κB reporter, and a Renilla control.
The cells were treated with stimuli for 12 h, harvested, and tested
for luciferase activity.
MDP-(l) (2) activates
the Nod2/NF-κB
pathway at higher concentrations. Hek293T cells were transfected with
(±)-Nod DNA (0.1 ng), NF-κB reporter, and a Renilla control.
The cells were treated with stimuli for 12 h, harvested, and tested
for luciferase activity.The in vitro interaction between Nod2 and MDP is
pH-dependent (Figure 6), with the pH range
from 5.0 to 6.5 giving maximal
binding. The data suggest that in vivo binding could occur in an acidic
cellular compartment, a model supported by cellular assays showing
pH-dependent internalization of MDP.[29,30] Girardin and
co-workers showed that the internalization of MDP is optimal in the
pH range from 5.5 to 6.5, which corresponds with the MDP/Nod2 binding
data.
Figure 6
Nod2 and MDPs interact under a variety of conditions. The pH of
Nod2 was adjusted before application to the MDP chip. Nod2 was preincubated
with 10 μM ATP or ADP before application to the MDP chip. The
relative resonance signal was recorded after 10 min.
Nod2 and MDPs interact under a variety of conditions. The pH of
Nod2 was adjusted before application to the MDP chip. Nod2 was preincubated
with 10 μM ATP or ADP before application to the MDP chip. The
relative resonance signal was recorded after 10 min.Nod2 is predicted to have ATP binding capabilities,
as it has Walker
A and Walker B regions.[31] The ATP binding
capacities of the protein have been suggested to be important for
oligomerization, protein–protein interactions, and subsequent
activation.[32] To test whether nucleotide
binding is necessary for Nod2 to bind to MDP, we measured Nod2 binding
to MDP with and without ATP/ADP. Nod2 binds to MDP with no appreciable
change in the presence and absence of 10 μM ATP/ADP (Figure 6), suggesting that ATP/ADP is not necessary for
binding of Nod2 to MDP.Prior to our investigation, the mechanism
of Nod2 activation of
NF-κB by treatment with MDP was unclear. We have employed a
biochemical approach to demonstrate that Nod2 binds directly to bacterial
cell wall fragments. Recombinant Nod2 and the synthetic MDP tools
allowed for the development of in vitro assay to detect binding. The
assay that we have developed will be a valuable asset in screening
for inhibitors/activators of the Nod2 signaling pathway and determining
whether Nod2 is able to differentiate commensal versus pathogenic
bacteria. In addition, the assay will be useful in determining whether
the Nod2 Crohn’s mutants are capable of binding to MDP. This
is the first biochemical evidence to show an interaction between the
two molecules, and it establishes that MDP is a high-affinity ligand
for Nod2.
Authors: Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho Journal: Nature Date: 2001-05-31 Impact factor: 49.962
Authors: Stephen E Girardin; Leonardo H Travassos; Mireille Hervé; Didier Blanot; Ivo G Boneca; Dana J Philpott; Philippe J Sansonetti; Dominique Mengin-Lecreulx Journal: J Biol Chem Date: 2003-07-18 Impact factor: 5.157
Authors: Stephen E Girardin; Ivo G Boneca; Jérôme Viala; Mathias Chamaillard; Agnès Labigne; Gilles Thomas; Dana J Philpott; Philippe J Sansonetti Journal: J Biol Chem Date: 2003-01-13 Impact factor: 5.157
Authors: Dana J Philpott; Matthew T Sorbara; Susan J Robertson; Kenneth Croitoru; Stephen E Girardin Journal: Nat Rev Immunol Date: 2013-12-13 Impact factor: 53.106
Authors: Clare E Bryant; Selinda Orr; Brian Ferguson; Martyn F Symmons; Joseph P Boyle; Tom P Monie Journal: Pharmacol Rev Date: 2015 Impact factor: 25.468
Authors: Klare M Lazor; Junhui Zhou; Kristen E DeMeester; Elizabeth A D'Ambrosio; Catherine L Grimes Journal: Chembiochem Date: 2019-03-21 Impact factor: 3.164